Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2019 16:45 ET | Source: Galapagos NV

Klinisch ontwikkelingsprogramma met MOR106 in eczeem gestopt voor futiliteit

Mechelen, België; 28 oktober 2019; 20.15 CET; gereglementeerde informatie - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR), Galapagos NV (Euronext & NASDAQ: GLPG) hebben...
October 28, 2019 16:45 ET | Source: Galapagos NV

MOR106 clinical development in atopic dermatitis stopped for futility

20.15 CET; regulated information - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the end of the clinical...
October 25, 2019 16:01 ET | Source: Galapagos NV

Galapagos ontvangt transparantieverklaring van Wellington Management Group LLP

Mechelen, België; 25 oktober 2019, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van Wellington...
October 25, 2019 16:01 ET | Source: Galapagos NV

Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from Wellington Management Group LLP....
October 24, 2019 16:01 ET | Source: Galapagos NV

Sterk derde kwartaal 2019 met solide balans voor verdere R&D-groei

Financiële resultaten over de eerste negen maanden: Omzet van €752,5 miljoenOperationele winst van €393,0 miljoenNettowinst van €265,3 miljoenKaspositie op 30 september 2019 van €5,6 miljard ...
October 24, 2019 16:01 ET | Source: Galapagos NV

Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

First nine month financial results: Group revenues of €752.5 millionOperating profit of €393.0 millionNet profit of €265.3 millionCash and cash equivalents on 30 Sept 2019 of €5.6 billion ...
October 10, 2019 18:00 ET | Source: Galapagos NV

GILEAD EN GALAPAGOS KONDIGEN VEILIGHEIDS-EN WERKZAAMHEIDSRESULTATEN AAN OVER FILGOTINIB NA 52 WEKEN IN FINCH 1 EN 3 STUDIES IN REUMA

Foster City, Calif. en Mechelen, België; 11 oktober 2019; 0.00 CET; – Gilead Sciences, Inc. (NASDAQ: GILD) en Galapagos NV (Euronext & NASDAQ: GLPG) maakten vandaag bekend dat de...
October 10, 2019 18:00 ET | Source: Galapagos NV

GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from...
October 07, 2019 16:01 ET | Source: Galapagos NV

Galapagos ontvangt transparantieverklaring van Wellington Management Group LLP

Mechelen, België; 7 oktober 2019, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van Wellington...
October 07, 2019 16:01 ET | Source: Galapagos NV

Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP. ...